Ongoing Phase 2a Study in Parkinson’s Disease

A Multicenter, Single-Dose, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson’s Disease related Constipation.

The study has been published on ClinicalTrials.gov under the title ‘Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson’s Disease Related Constipation (RASMET)’ and ClinicalTrials.gov Identifier NCT03047629. Also, there is some additional information about the study on the Michael J. Fox Foundation website.

The single-dose stage has completed enrollment of 10 patients. The multiple-dose randomized study began in September 2017, and will be conducted at sites in New York (NY), Philadelphia (PA), Cleveland (OH), Cincinnati (OH), Tampa (FL), Sarasota (FL), Boca Raton (FL), St. Petersburg (FL), Jacksonville (FL), Port Charlotte (FL), Denver (CO), Los Angeles (CA), Washington (DC), Detroit (MI) and Hershey (PA). Forty (40) patients with Parkinson’s Disease and constipation will be included. For further information, please go to ClinicalTrials.gov or contact us using the Contact Form on this website.